Contribute Try STAT+ Today

On Wednesday, five health data analytics companies announced they have banded together to form an industry consortium that aims to transform the way new drugs and devices make their way to patients.

The digitization of medical records has opened up access to reams of data about patient outcomes in the past decade, but not all of it has found a use. “Real-world data, in and of itself, is not that interesting, right?” said Michael Vasconcelles, chief medical officer of Flatiron Health, the initiator of the new alliance. “It’s really the insights that one gleans from asking important scientific questions that then can be answered or informed by those data.” In other words, maybe that data can grow up to become real-world evidence, or RWE.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.